Quantification of "end products" of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways-implications for modern clinical chemistry

Biomarkers

Volumn 18, Issue 5, 2013, Pages 375-378

  Karsdal, Morten A ^a   Bay Jensen, Anne Christine ^a   Leeming, Diana Julie ^a   Henriksen, Kim ^a   Christiansen, Claus ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Growth factors cytokines inflammatory mediators; Hematology; Proteomics

Indexed keywords

CYTOKINE;

DISEASE COURSE; INFLAMMATION; REVIEW; TISSUES;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CYTOKINES; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INFLAMMATION MEDIATORS; ORGAN SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 84880557425     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.789084     Document Type: Review

References (28)

1. Allin KH, Nordestgaard BG. (2011). Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 48: 155-70.
2. Barascuk N, Veidal SS, Larsen L, et al. (2010). A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem 43: 899-904.
3. Bay-Jensen AC, Liu Q, Byrjalsen I, et al. (2011). Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM - increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 44:423-9.
4. Bonilla-Hernan MG, Miranda-Carus ME, Martin-Mola E. (2011). New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxford) 50:1542-50.
5. Conrozier T, Poole AR, Ferrand F, et al. (2008). Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. Clin Exp Rheumatol 26:430-5.
6. Garnero P, Ferreras M, Karsdal MA, et al. (2003). The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859-67.
7. Karsdal MA, Delvin E, Christiansen C. (2011). Protein fingerprints - relying on and understanding the information of serological protein measurements. Clin Biochem 44:1278-9.
8. Karsdal MA, Henriksen K, Leeming DJ, et al. (2009). Biochemical markers and the FDA critical path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 14:181-202.
9. Karsdal MA, Henriksen K, Leeming DJ, et al. (2010). Novel combinations of post-translational modification (PTM) neo-epitopes provide tissue-specific biochemical markers - are they the cause or the consequence of the disease? Clin Biochem 43:793-804.
10. Karsdal MA, Nielsen MJ, Sand JM, et al. (2012a). Extracellular matrix remodeling: the common denominator in connective tissue diseases possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol 11:70-92.
11. Karsdal MA, Schett G, Emery P, et al. (2012b). IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum 42:131-9.
12. Kishimoto T. (2005). IL-6: from laboratory to bedside. Clin Rev Allergy Immunol 28:177-86.
13. Leeming D, He Y, Veidal S, et al. (2011). A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 16:616-28.
14. Mocsai A, Ruland J, Tybulewicz VL. (2010). The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 10: 387-402.
15. Murphy G, Nagase H. (2008). Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol 4:128-35
16. Pamuk ON, Tsokos GC (2010). Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases. Arthritis Res Ther 12:222.
17. Riccaboni M, Bianchi I, Petrillo P. (2010). Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 15:517-30.
18. Rosenquist C, Fledelius C, Christgau S, et al. (1998). Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:2281-9.
19. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. (2001). Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21:351-72.
20. Sondergaard BC, Henriksen K, Wulf H, et al. (2006). Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 14:738-48.
21. Vassiliadis E, Veidal SS, Simonsen H, et al. (2011). Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers 16:426-33.
22. Veidal SS, Karsdal MA, Nawrocki A, et al. (2011a). Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair 4:22.
23. Veidal SS, Karsdal MA, Vassiliadis E, et al. (2011b). MMP mediated degradation of type VI collagen is highly associated with liver fibrosis - identification and validation of a novel biochemical marker assay. PLoS One 6:e24753.
24. Veidal SS, Larsen DV, Chen X, et al. (2012). MMP mediated type V collagen degradation (C5M) is elevated in ankylosing spondylitis. Clin Biochem 45:541-6.
25. Veidal SS, Vassiliadis E, Bay-Jensen AC, et al. (2010). Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair 3:5.
26. Wislowska M, Jakubicz D, Stepien K, Cicha M. (2009). Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis. Rheumatol Int 29: 1403-9.
27. Wong BR, Grossbard EB, Payan DG, Masuda ES. (2004). Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13:743-62.
28. Zou W, Kitaura H, Reeve J, et al. (2007). Syk, c-Src, the {alpha}v{beta}3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol 176:877-88.